Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. It also offers Argus II Retinal Prosthesis System, an FDA and CE Mark approved device for treating retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California with an additional office in Lausanne, Switzerland.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone818-833-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.96 million
Profitability
Miscellaneous
Employees112
Next Earnings Date3/6/2019 (Estimated)
OptionableOptionable
Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions
What is Second Sight Medical Products' stock symbol?
Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."
How were Second Sight Medical Products' earnings last quarter?
Second Sight Medical Products Inc (NASDAQ:EYES) released its quarterly earnings results on Tuesday, August, 7th. The medical device company reported ($0.12) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.02. The medical device company earned $1.91 million during the quarter, compared to analyst estimates of $2.21 million. Second Sight Medical Products had a negative net margin of 408.41% and a negative return on equity of 638.26%. View Second Sight Medical Products' Earnings History.
When is Second Sight Medical Products' next earnings date?
What price target have analysts set for EYES?
1 equities research analysts have issued 12 month price targets for Second Sight Medical Products' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Second Sight Medical Products' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 535.5% from the stock's current price. View Analyst Price Targets for Second Sight Medical Products.
What is the consensus analysts' recommendation for Second Sight Medical Products?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Second Sight Medical Products.
Has Second Sight Medical Products been receiving favorable news coverage?
News headlines about EYES stock have been trending somewhat positive on Saturday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Second Sight Medical Products earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
Who are some of Second Sight Medical Products' key competitors?
Some companies that are related to Second Sight Medical Products include Cutera (CUTR), Zynex (ZYXI), Helius Medical Technologies (HSDT), Fonar (FONR), Stereotaxis (STXS), BioSig Technologies (BSGM), Edap Tms (EDAP), IRIDEX (IRIX), Soleno Therapeutics (SLNO), Viveve Medical (VIVE), Precision Optics (PEYE), Digirad (DRAD), ENDRA Life Sciences (NDRA), Non-Invasive Monitoring Systems (NIMU) and Vaso (VASO).
What other stocks do shareholders of Second Sight Medical Products own?
Who are Second Sight Medical Products' key executives?
Second Sight Medical Products' management team includes the folowing people:
- Mr. Jonathan Will McGuire, CEO, Pres & Director (Age 56)
- Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 55)
- Gunnar Bjorg, Founder
- Mr. John T. Blake, CFO & Corp. Sec. (Age 43)
- Mr. William Patrick Ryan, Chief Operating Officer (Age 58)
When did Second Sight Medical Products IPO?
(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.
How do I buy shares of Second Sight Medical Products?
Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Second Sight Medical Products' stock price today?
One share of EYES stock can currently be purchased for approximately $0.7868.
How big of a company is Second Sight Medical Products?
Second Sight Medical Products has a market capitalization of $60.06 million and generates $7.96 million in revenue each year. The medical device company earns $-28,510,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Second Sight Medical Products employs 112 workers across the globe.
What is Second Sight Medical Products' official website?
How can I contact Second Sight Medical Products?
Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD BLDG. 3, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]
MarketBeat Community Rating for Second Sight Medical Products (NASDAQ EYES)
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days.
